Cephalothin Sodium

CHEMBL1632 Phase 4 承認済み Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
418.4 g/mol
LogP
Phase
4

The sodium salt preparation of cephalothin was the standard parenteral first-generation cephalosporin formulation used in clinical practice until it was gradually displaced by newer agents. It retains the same antibacterial spectrum as cephalothin. The drug is now of primarily historical significance.

分子量

418.4000 g/mol

TPSA

169.00 Ų

作用機序

Disrupts bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting the final transpeptidation step of peptidoglycan synthesis. The resulting cell wall defects cause osmotic instability and bacteriolysis.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

機序

Disrupts bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting the final transpeptidation step of peptidoglycan synthesis. The resulting cell wall defects cause osmotic instability and bacteriolysis.

2D構造

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CC(=O)OCC1=C(C(=O)[O-])N2C(=O)[C@@H](NC(=O)Cc3cccs3)[C@H]2SC1.[Na+]

InChI

InChI=1S/C16H16N2O6S2.Na/c1-8(19)24-6-9-7-26-15-12(14(21)18(15)13(9)16(22)23)17-11(20)5-10-3-2-4-25-10;/h2-4,12,15H,5-7H2,1H3,(H,17,20)(H,22,23);/q;+1/p-1/t12-,15-;/m1./s1

Molecular Formula

C16H15N2NaO6S2

HBD / HBA

1 / 8

回転可能結合数

7

重原子数

27

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

よくある質問

The sodium salt preparation of cephalothin was the standard parenteral first-generation cephalosporin formulation used in clinical practice until it was gradually displaced by newer agents. It retains the same antibacterial spectrum as cephalothin. The drug is now of primarily historical significance.

Disrupts bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting the final transpeptidation step of peptidoglycan synthesis. The resulting cell wall defects cause osmotic instability and bacteriolysis.

Yes, Cephalothin Sodium is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1632. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 23675321. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

医学的免責事項

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.